Rhythm Pharmaceuticals (RYTM) Equity Average (2017 - 2025)
Historic Equity Average for Rhythm Pharmaceuticals (RYTM) over the last 9 years, with Q3 2025 value amounting to $68.5 million.
- Rhythm Pharmaceuticals' Equity Average rose 17079.59% to $68.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.5 million, marking a year-over-year increase of 17079.59%. This contributed to the annual value of $95.7 million for FY2024, which is 5588.05% down from last year.
- Per Rhythm Pharmaceuticals' latest filing, its Equity Average stood at $68.5 million for Q3 2025, which was up 17079.59% from $3.5 million recorded in Q2 2025.
- In the past 5 years, Rhythm Pharmaceuticals' Equity Average registered a high of $366.3 million during Q2 2021, and its lowest value of $3.5 million during Q2 2025.
- In the last 5 years, Rhythm Pharmaceuticals' Equity Average had a median value of $201.0 million in 2023 and averaged $178.9 million.
- Within the past 5 years, the most significant YoY rise in Rhythm Pharmaceuticals' Equity Average was 17079.59% (2025), while the steepest drop was 9302.54% (2025).
- Rhythm Pharmaceuticals' Equity Average (Quarter) stood at $303.2 million in 2021, then dropped by 10.05% to $272.7 million in 2022, then tumbled by 32.67% to $183.6 million in 2023, then crashed by 91.03% to $16.5 million in 2024, then surged by 315.58% to $68.5 million in 2025.
- Its Equity Average stands at $68.5 million for Q3 2025, versus $3.5 million for Q2 2025 and $20.3 million for Q1 2025.